Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?

Q&A and discussion

Date

13 Sep 2024

Session

Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Visiting the basics: Rationale and MoA

Presenter: Susana Banerjee

Session: Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?

Resources:

Slides

Webcast

ADCs in ovarian cancer

Presenter: Domenica Lorusso

Session: Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?

Resources:

Slides

Webcast

ADCs in endometrial and cervical cancer

Presenter: Toon Van Gorp

Session: Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?

Resources:

Slides

Webcast

How to manage safety

Presenter: Ilaria Colombo

Session: Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.